

**AMENDMENT TRANSMITTAL LETTER (Large Entity)**Applicant(s): **Cockerill et al.**

Docket No.

PU3743USW

Application No.

10/030,527

Filing Date

1/9/02

Examiner

Bruck Kifle

Customer No.

23347

Group Art Unit

1624

Confirmation No.

4128Invention: **ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS****COMMISSIONER FOR PATENTS:**

Transmitted herewith is an amendment in the above-identified application.


The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	30 -	32 =	0	x \$18.00	\$0.00
INDEP. CLAIMS	2 -	3 =	0	x \$88.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

- ☒ No additional fee is required for amendment.
- ☐ Please charge Deposit Account No. _____ in the amount of _____
- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☒ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 07-1392
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☐ Payment by credit card. Form PTO-2038.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.


Signature

John L. Lemanowicz, Reg. No. 37,388
Attorney for Applicants
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8247
Facsimile: (919) 483-7988

Dated:

2/10/05

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on


(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

CC:

P11LARGE/REV09



FEB. 10. 2005 3:22PM GLAXO WELLCOME
Atty. Docket No.: PUS743USV

NO. 6425 P. 5

BEST AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Cockerill et al

Serial No.: 10/030,527

Filing Date: January 9, 2002

For: ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS

Examiner: B. Kifle

Art Unit: 1624

Box Issue fee
Commissioner for Patents
Washington D.C. 20231

AMENDMENT UNDER 37 C.F.R. 1.312

Sir:

This paper is filed, after receipt of Notice of Allowance, under 37 C.F.R. 1.312 to correct an error in the claims.

Please amend the above-identified application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 7 of this paper.